ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (NASDAQ: IMGN) has announced a conference call on May 6, 2022, at 8:00 a.m. ET, to discuss its Q1 2022 operating results and provide business updates. The call can be accessed by dialing (877) 621-5803 with conference ID 5444669, or through the company’s website. ImmunoGen focuses on developing antibody-drug conjugates aimed at improving cancer treatment outcomes and enhancing patient quality of life. Their mission is encapsulated in the phrase “TARGET A BETTER NOW™”.

Positive

• Anticipation of Q1 2022 results may indicate ongoing business activity.
• Continued focus on developing innovative antibody-drug conjugates for cancer treatment.

Negative

• No specific financial results or metrics provided, leaving investors without key financial insights.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, dial (877) 621-5803; the conference ID is 5444669. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005100/en/

INVESTOR RELATIONS AND MEDIA CONTACTS

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

What is the purpose of ImmunoGen's conference call on May 6, 2022?

The conference call will discuss Q1 2022 operating results and provide updates on business developments.

How can I access ImmunoGen's conference call?

The call can be accessed by phone at (877) 621-5803 using conference ID 5444669, or via the company's website.

What does ImmunoGen specialize in?

ImmunoGen specializes in developing antibody-drug conjugates to improve cancer treatment outcomes.

What is ImmunoGen's slogan?

ImmunoGen's commitment is encapsulated in the slogan 'TARGET A BETTER NOW™'.